Company Overview
Company Type: Public Company
Company Status: Operating Subsidiary
Website: www.rakovinatherapeutics.com
Number of Employees: -
Ticker: RKV (TSXV)
Year Founded: -


Business Description
Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on novel series of small-molecule DNA-damage response inhibitors (DDRi). Its preclinical product pipeline include kt-2000, a next generation oral targeted small molecule PARP inhibitors; kt-3000, a bi-functional small-molecule drug candidate; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
7.7
EBITDA
(2.1)
Total Enterprise Value
7.8
TEV/EBITDA
NM
EBIT
(2.6)
Cash & ST Invst.
1.2
P/Diluted EPS Before Extra
NM
Net Income
(2.6)
Total Debt
1.3
Price/Tang BV
47.1x
Total Assets
6.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Sep-25-2023

Key Professionals
Name
Title
Bacha, Jeffrey A.
Executive Chairman
Daugaard, Mads 
President, CEO & Chief Scientific Officer
Hyman, David
CFO & Corporate Secretary
Langlands, John 
Chief Operating Officer

Key Board Members
Name
Title
Bacha, Jeffrey A.
Executive Chairman
De Lucrezia, Alfredo Javier
Vice Chairman
Brown, Dennis M.
Chairman of Scientific Advisory Board & Independent Director
Liggett, Michael 
Independent Director
Post, Leonard E.
Member of Scientific Advisory Board
Sankar, Neil 
Member of Scientific Advisory Board
Shen, Wang 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
1008 Beach Avenue Suite 105 | Vancouver, BC | V6E 1T7 | Canada

Parent Company
NewGen Therapeutics, Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.11
Market Cap (mm)
7.7
Open
 0.11
Shares Out. (mm)
69.8
Previous Close
 0.11
Float %
54.3%
Change on Day
0.0050
Shares Sold Short (mm)
-
Change % on Day
4.8%
Dividend Yield %
-
Day High/Low
 0.11/ 0.11
Diluted EPS Excl. Extra Items
(0.04)
52 wk High/Low
 0.20/ 0.09
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0005
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
(0.22)


 
Delayed Quote** | Last Updated on Sep-25-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Vincero Capital Corp.
As of March 25, 2021, Vincero Capital Corp. was acquired by Certain Worldwide Rights of NewGen Therapeutics, Inc., in a reverse merger transaction. Vincero Capital Corp. does not have significant operations. It engages in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

United States and Canada
Asset Management and Custody Banks
-
1.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-02-2023
May-29-2023
Private Placement
Target
Rakovina Therapeutics Inc. (TSXV:RKV)


1.10
Mar-3-2022
-
Shelf Registration
Target
Rakovina Therapeutics Inc. (TSXV:RKV)


39.44
Dec-31-2021
-
Shelf Registration
Target
Rakovina Therapeutics Inc. (TSXV:RKV)


39.51
Nov-10-2020
Mar-25-2021
Private Placement
Target
Rakovina Therapeutics Inc. (TSXV:RKV)


3.62
May-27-2020
Mar-25-2021
Merger/Acquisition
Buyer
Vincero Capital Corp.
Rakovina Therapeutics Inc. (TSXV:RKV)

4.35
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-04-2023
Company Conference Presentations
Rakovina Therapeutics Inc. Presents at Emerging Growth Conference 63, Oct-04-2023 02:55 PM
Sep-23-2023
Company Conference Presentations
Rakovina Therapeutics Inc. Presents at GCFF Conference 2023, Sep-23-2023 10:40 AM
Jun-28-2023
Annual General Meeting
Rakovina Therapeutics Inc., Annual General Meeting, Jun 28, 2023
Jun-21-2023
Company Conference Presentations
Rakovina Therapeutics Inc. Presents at MedInvest Oncology Investor Conference 2023, Jun-21-2023 05:00 PM
Jun-14-2023
Company Conference Presentations
Rakovina Therapeutics Inc. Presents at Emerging Growth Conference, Jun-14-2023 03:10 PM

M&A Advisors
Blake, Cassels & Graydon LLP


Advisors
Most Recent Auditor
Davidson & Company LLP
M&A Advisors
Blake, Cassels & Graydon LLP


Most Recent Auditor
Davidson & Company


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Atrium Research
Cortellucci, Nicholas
Jul 26, 2023 07:28 AM
RKV
RKV: A Catalyst Heavy Oncology Story
Notes
7


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Edison Oncology Holding Corp.

24,265,625

34.75

2.7

May-24-2023


De Lucrezia, Alfredo Javier

4,925,000

7.05

0.6

Aug-28-2023


Bacha B.Sc., M.B.A., Jeffrey A.

1,635,000

2.34

0.2

Aug-28-2023


Brown B.Sc., M.A., Ph.D., Dennis M.

625,000

0.90

0.1

Aug-28-2023


Hyman CA, CBV, David

315,000

0.45

0.0

Aug-28-2023


Daugaard, Mads 

100,000

0.14

0.0

Aug-28-2023


Colangelo, Benito James

50,000

0.07

0.0

Aug-28-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
De Lucrezia, Alfredo Javier
4,925,000
50,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Nov-29-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-29-2023
Jun-30-2023
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Interim Financial Statements
288 KB
Aug-29-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
News Releases
134 KB
Jun-28-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
News Releases
66 KB
Jun-06-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Material Change Report
80 KB
Jun-06-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Documents Affecting the Rights of Security Holders
661 KB
Jun-06-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Documents Affecting the Rights of Security Holders
880 KB
Jun-01-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Management Proxy Materials
40 KB
Jun-01-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Management Proxy Materials
18 KB
Jun-01-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Management Proxy Materials
221 KB
Jun-01-2023
-
Rakovina Therapeutics Inc. (TSXV:RKV)
SEDAR
Management Proxy Materials
17 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
De Lucrezia, Alfredo Javier (Vice Chairman)
Aug-14-2023
Common Shares
50,000
5,102
Open Market Acquisition
1.03
Multiple
Bacha B.Sc., M.B.A., Jeffrey A. (Executive Chairman)
Feb-09-2023
Common Shares
50,000
7,160
Open Market Acquisition
3.15
Multiple
De Lucrezia, Alfredo Javier (Vice Chairman)
Feb-08-2023
Common Shares
75,000
9,201
Open Market Acquisition
1.56
Multiple
Bacha B.Sc., M.B.A., Jeffrey A. (Executive Chairman)
Jan-18-2023
Common Shares
60,000
9,610
Open Market Acquisition
3.93
Multiple
Hyman CA, CBV, David (CFO & Corporate Secretary)
Jan-18-2023
Common Shares
70,000
10,374
Open Market Acquisition
28.57
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bacha, Jeffrey A.
Executive Chairman
-
-

De Lucrezia, Alfredo Javier
Vice Chairman
-
-

Brown, Dennis M.
Chairman of Scientific Advisory Board & Independent Director
-
-

Liggett, Michael 
Independent Director
(778) 802-9806
-
liggett@icotherapeutics.com.
Post, Leonard E.
Member of Scientific Advisory Board
-
-

Sankar, Neil 
Member of Scientific Advisory Board
-
-

Shen, Wang 
Member of Scientific Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bacha, Jeffrey A.
Executive Chairman
-
-

Daugaard, Mads 
President, CEO & Chief Scientific Officer
-
-

Hyman, David
CFO & Corporate Secretary
-
-
-
Langlands, John 
Chief Operating Officer
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
